share_log

BTIG Initiates Coverage On Kymera Therapeutics With Buy Rating, Announces Price Target of $60

BTIG Initiates Coverage On Kymera Therapeutics With Buy Rating, Announces Price Target of $60

BTIG对Kymera Therapeutics启动覆盖,评级为买入,目标价格为60美元。
Benzinga ·  2024/12/10 12:56  · 评级/大行评级

BTIG analyst Jeet Mukherjee initiates coverage on Kymera Therapeutics (NASDAQ:KYMR) with a Buy rating and announces Price Target of $60.

BTIG 分析师Jeet Mukherjee开始对Kymera Therapeutics(纳斯达克:KYMR)进行覆盖,给出买入评级,并宣布目标价为60美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发